TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER

Тазовая хирургия и онкология

E. B. Mironova¹  V. A. Khailenko²  V. V. Karaseva²  P. S. Feoktistova³  Ya. M. Kolesnikov⁴  O. V. Zharkova⁴  K. V. Vyalova⁴ 

[1] Clinical Hospital Eighty-One, Federal Biomedical Agency of Russia, Seversk;N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow;Nizhnevartovsk Oncology Dispensary, Khanty-Mansiysk Autonomous Oncology Dispensary;Regional Clinical Oncology Dispensary, Kemerovo;

关键词: metastatic colorectal cancer;    chemotherapy;    targeted therapy;    bevacizumab;   

DOI  :  10.17650/2220-3478-2013-0-1-54-57

来源: DOAJ

【 摘 要 】

The efficiency of 2 programs of chemotherapy in the treatment of 46 patients with disseminated colorectal cancer. The program of chemo-therapy of oxaliplatin + capecitabine (ОХА/САР), established authors, with bevacizumab (BEV) showed the best results compared with oxaliplatin + 5-fluorouracyl + leukovorin (ОХА/5-FU/LV) with bevacizumab. The overall efficiency OXA/5-FU/LV/BEV amounted to 40.91 ± 8.6 %, 4.54 ± 5.1 % of total regressions. The overall effect of therapy in the OXA/CAP/BEV amounted to 45.83 ± 8.6 %, full regression was achieved in 4 patients, which amounted to 16.66 ± 5.6 %. The median time to progression in the first group of patients was 8.3 months, in the second – 9.8 months. Clinical application of involving bevacizumab in combination with different modes of chemotherapy in patients with disseminated colorectal cancer is acceptable and manageable toxicity that doesn't require reduction of doses.

【 授权许可】

Unknown